Carolyn Bertozzi focused on bioorthogonal chemistry in 1996 and won the Nobel Prize in 2022 This is how her discovery got to cancer clinical trials

Lawrence Fong appointed senior vice president and director of the Fred Hutch Translational Science and Therapeutics Division

Lawrence Fong was appointed senior vice president and director of Fred Hutch’s Translational Science and Therapeutics Division, effective Dec. 1.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

The REZILIENT3 trial, a global phase III clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations, met its primary endpoint of progression-free survival at a planned interim analysis.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Penn Medicine launches first human clinical trial to test precision form of FLASH proton therapy

A new form of proton therapy designed to deliver cancer-killing radiation therapy in less than a second, through fewer total sessions, with potentially less risk of damaging side effects, is now being tested in a phase I clinical trial at the Abramson Cancer Center of the University of Pennsylvania.

September 11, 2026

Vol.52 No.33

Clinical Roundup

SANRECO phase II study of divesiran in polycythemia vera meets primary endpoint

The SANRECO phase II trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera, met its primary endpoint and secondary endpoints. The 36-week, randomized, double-blind, placebo-controlled portion of the trial administered divesiran subcutaneously (6 mg/kg) every six weeks or every twelve weeks.

August 14, 2026

Vol.52 No.32

Clinical Roundup

Phase III XPORT-EC-042 trial in endometrial cancer does not meet primary endpoint

The phase III XPORT-EC-042 trial, evaluating selinexor as a maintenance-only therapy compared to placebo in adult patients with TP53 wild-type advanced or recurrent endometrial cancer, did not meet its primary endpoint of progression free survival.

August 07, 2026

Vol.52 No.31

Clinical Roundup

How to boost enrollment of Black and Hispanic patients in pediatric clinical trials

While Black and Hispanic families are enthusiastic about research participation, other provider- and systems-focused factors may influence their involvement in pediatric oncology clinical trials, according to a study led by researchers at UT Southwestern Medical Center and Dana-Farber/Mass General.

August 07, 2026

Vol.52 No.31

Carolyn Bertozzi focused on bioorthogonal chemistry in 1996 and won the Nobel Prize in 2022

This is how her discovery got to cancer clinical trials

YOU MAY BE INTERESTED IN

Lawrence Fong appointed senior vice president and director of the Fred Hutch Translational Science and Therapeutics Division

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

Penn Medicine launches first human clinical trial to test precision form of FLASH proton therapy

SANRECO phase II study of divesiran in polycythemia vera meets primary endpoint

Phase III XPORT-EC-042 trial in endometrial cancer does not meet primary endpoint

How to boost enrollment of Black and Hispanic patients in pediatric clinical trials

Renew today!

Subscriber content

Never miss an issue!

Login